Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies.
iSPERSE™ is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs.
iSPERSE™ can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.
Can be used with a broad range of drugs, small molecule to biologic
Can deliver large doses into lungs (tens of milligrams) with high lung delivery efficiency
Can be used with any device (ie, metered-dose, reservoir, or blister-based inhalers)
Avoids first-pass effect and systemic side-effects, with improved PK profile compared to oral delivery
Can be administered to all patients due to its high dispersibility over a wide range of flow rates allowing for efficient penetration deep into the lung
Broad IP portfolio into 2030s
PULMATRiX is currently
studying the potential for iSPERSE™
to improve the lives of patients living with:
As we advance our mission to develop and
commercialize novel and transformational medicines,
we regularly share the progress of our research.
To learn more about our science and research findings,
download these PDFs: